Jubilant Pharmova Limited has informed the Exchange about General Updates-Jubilant Pharmova announces Completion of Pharmacovigilance Inspectionby the USFDA with No Observations

Jubilant Pharmova has cleared a Pharmacovigilance inspection conducted by the US FDA with No Observations. Pharmacovigilance inspections assess a company's systems for monitoring and reporting the safety of drugs once they are in the market. A 'No Observations' outcome means the US FDA inspectors did not flag any procedural lapses, data gaps, or compliance violations during the audit. This is a positive regulatory outcome, indicating that Jubilant Pharmova's drug safety monitoring practices meet US FDA expectations. The company had previously faced some regulatory scrutiny on this front, so a clean inspection removes a key overhang.